KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Consolidated Net Income: 2009-2025

Historic Consolidated Net Income for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $175.2 million.

  • Halozyme Therapeutics' Consolidated Net Income rose 27.89% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 51.72%. This contributed to the annual value of $444.1 million for FY2024, which is 57.71% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Consolidated Net Income of $175.2 million as of Q3 2025, which was up 6.11% from $165.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Consolidated Net Income high stood at $216.6 million for Q3 2021, and its period low was $22.7 million during Q2 2022.
  • Over the past 3 years, Halozyme Therapeutics' median Consolidated Net Income value was $93.2 million (recorded in 2024), while the average stood at $107.6 million.
  • In the last 5 years, Halozyme Therapeutics' Consolidated Net Income soared by 557.07% in 2021 and then crashed by 75.20% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Consolidated Net Income (Quarterly) stood at $66.8 million in 2021, then declined by 13.58% to $57.7 million in 2022, then soared by 47.98% to $85.4 million in 2023, then soared by 60.46% to $137.0 million in 2024, then grew by 27.89% to $175.2 million in 2025.
  • Its last three reported values are $175.2 million in Q3 2025, $165.1 million for Q2 2025, and $118.1 million during Q1 2025.